Disclosures SUCCESFUL INSULIN THERAPY DISCOVERY OF INSULIN 9/28/2017 THE HORROR OF DIABETES
|
|
- Everett Lester
- 6 years ago
- Views:
Transcription
1 Disclosures Innovations in the Treatment of Diabetes Dennis G. Karounos, M.D. Associate Professor of Internal Medicine, Immunology, Physiology, Graduate Center of Nutrition UKMC & VAMC Grants/research supported by: NIH, Department of Veterans Affairs, Novo Nordisk A/S, Eli Lilly, Amylin Pharmaceuticals, Astra/Zenaca, Bristol-Myer Squib, Peptor Ltd, Diamyd, Osiris, Spherix Consultant: Viacyte Objectives 1. Discuss new therapies of diabetes 2. Report on the development of an artificial pancreas 3. Review strategies to prevent diabetes THE HORROR OF DIABETES Pre-Insulin Era: 50% Children die within 1yr of diagnosis Case Presentation: J.L. age 3, Weight 15# dehydration, emaciation (Dec. 15, 1922) Treatment options Starvation therapy Insulin DISCOVERY OF INSULIN SUCCESFUL INSULIN THERAPY Dr. Frederick Banting & Charles Best (medical student) Bantings Plan: ligate pancreatic duct... isolate internal secretion (of islet)... to relieve glycosuria Notebook with experimental idea Oct. 31, days after insulin therapy, Jan Wt. Increased to 29 # JAMA Feb. 15,
2 Growing Prevalence of Diabetes 2016 National Diabetes Fact Sheet, CDC (current) 29 million (7.8% population) 25% undiagnosed 86 million w/ prediabetes Age > 65 yrs: 21.5% Year 2050: 1:3 Americans with diabetes 33% with diabetes!!!!! 2016 CDC Diabetes Fact Sheet Source: DANGEROUS TOLL: Diabetes in Kentucky Over 424,670 (12.5%) adult Kentuckians have diabetes (national rate 8.1%) nearly doubled from 2000 to 2014 Kentucky ranked in the top 10 in US (unfortunately we are not talking about basketball) An additional 138,000 are undiagnosed CDC estimates that 1.1 million adults in KY have prediabetes (37%, 1 in 3) DM is seventh leading cause of death in Kentucky Source: Kentucky Cabinet for Health and Family Services Etiologic Classification Type 1 diabetes Immune mediated Idiopathic Latent Autoimmune Diabetes of Adults Type 2 diabetes Other specific types Genetic defects of beta cell Genetic defects in insulin action Endocrinopathies Gestational diabetes T1DM Pathogenesis: chronic autoimmune disease Insulitis: Lymphocytic Infiltration & Destruction of Islets in Type 1 Diabetes resulting in severe insulin deficiency Normal Islet Insulitis: arrow marks the ENEMY location Pre-diabetes in Type 1 Diabetes Plasma glucose level and oral glucose tolerance test are normal Decrease insulin secretion when measured with an intravenous glucose tolerance test Islet cell antibodies are detected: GAD antibodies, ICA512, & Insulin autoantibodies (miaa) Candidates for Diabetes Prevention Trials 2010 Criteria for Diagnosis of Diabetes 1. A1C 6.5%. The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.* OR 2. FPG 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.* OR 3. Two-hour plasma glucose 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.* OR 4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose 200 mg/dl (11.1 mmol/l). *In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing Source: American Diabetes Assoc. 2
3 Objective 1: Discuss new therapies of diabetes Late-stage Investigational: - Basal Insulins - Rapid Acting Insulins Islet Implants Artificial Pancreas A-CHAIN Gly SUBSTITUTION Asn B-CHAIN EXTENSION Arg Arg Newly approved: -Basal Insulins -Degludec -U-300 glargine insulin A-CHAIN Asn SUBSTITUTION B-CHAIN Gly EXTENSION Arg Arg Basal Insulin: Mechanism for Prolongation of Action: - Decrease solubility: protamine (NPH) or zinc: (UL) variable absorption - ph dependent precipitation (glargine) - Local albumin binding (detemir)-<24h duration - Multiple hexamer complexes but Gly soluble (degludec) Asn Arg Basal Insulins: : Basal Insulin Degludec Multiple Highly Complexed Hexamers New/ Investigational Basal Insulins Insulin lispro protamine suspension (ILPS) Pegylated insulin lispro ((LY )* Administration Status Peak Effective Duration QD or BID Approved 3 h 24 h outside USA < once daily Phase 3 Peakless h Degludec (NN1250) QD or 3x/wk FDA Approval 2015 Peakless >24 h *Bergenstal et al: Diabetes Care (2012) 35: Five ongoing Phase 3 IMAGINE trials T1DM/T2DM Gly Asn Arg Jonassen et al: Pharm Res (2012) 29:
4 : Basal Insulin Degludec -similar glycemic control -decreased nocturnal hypoglycemia Basal Insulin Degludec -similar glycemic control -decreased nocturnal hypoglycemia FDA Approval: Sep 2015: - degludec (Tresiba) & degludec/aspart 70/30 (Ryzodeg) Heller et al: Lancet (2012) 379:1494 FDA.gov Late-stage Investigational: -Ultra-Rapid Acting Insulins Ultra-Rapid Acting Insulins: Formulations to accelerate effect: - EDTA Zn chelation(decrease hexamers - Citrate masks charge (BIOD-238 & BIOD-250) - Hyaluronidases increase dispersion & absortpion - Nicotinamide+Arginine (FIAsp) Are New Basal Insulins Better? Are New Meal-time Insulins Better? Ultra-long-acting Basal Insulin - Evidence of reduced nocturnal hypoglycemia and decreased weight gain at comparable A1c lowering - Large phase 3 clinical trials underway to confirm hepatic and cardiovascular safety - Concentrated formulations (U-200, U-300) so reduced volume of administration Ultra-rapid-acting Bolus Insulin - Evidence for reduced postprandial hyperglycemia and potentially more convenient dosing - Larger phase 2 and 3 clinical trials underway to confirm efficacy, site tolerability and cardiovascular safety Ratner, RE: American Diabetes Association, Alexandria, VA 4
5 Islet Transplantation for Hypoglycemia Unawareness/Severe Hypoglcemia Islet Implants David M. Harlan Dia Care 2016;39: Caveat Emptor Pros - Improved glycemic control > 2yrs - Some with insulin indepencence (~40%) - Less traumatic procedure than whole pancreas transplant Cons - Procedure-related bleeds - Immunosupressionrelated complications (e.g. renal) - Malignancy risk - Cost - Most still require insulin - No clear survival benefit - Limited islet supply Islet Implants Chamber system for macroencapsulation of islets. Ludwig B et al. PNAS 2013;110: by National Academy of Sciences Islet Implants Bioartificial pancreas for transplantation without immunosuppression Islets isolated from donor pancreas Persistent graft function for ten months (stimulated C-peptide from 0.04 to 0.8 nmol/l) Improvement in A1c with reduction in insulin requirements (52 units to 43 units) Oxygen replenished by daily sc injection via oxygen port Stem cell-derived Islet Implants Bio-artificial pancreas for transplantation without immunosuppression Islet derived from embryonic stem cells- culture conditions optimized 5
6 Islet Implants: Macroencapsulation Bioartificial pancreas for transplantation without immunosuppression Xenotransplantation: Encapsulated porcine islets in patient with T1DM Long-term viability & function of transplanted encapsulated neonatal porcine islets Clinical trials underway 2017: Sentinel impants for safety & implant viability studies: sites: UCSD & U Alberta Xenotransplantation: Microencapsulation Encapsulated porcine islets in patient with T1DM Xenotransplantation: Encapsulated porcine islets in patient with T1DM 2016 Omentum embedded islet nodules: Insulin stain Glucagon stain Long-term viability & function of transplanted encapsulated neonatal porcine islets Long-term viability & function of transplanted encapsulated neonatal porcine islets Xenotransplantation: Encapsulated porcine islets in patient with T1DM 2016 Can Insulin be delivered by a pump? Long-term viability & function of transplanted encapsulated neonatal porcine islets 2 groups of 4 patients each 10,000 islets 20,000 islets First insulin pump - Dr. Arnold Kadish, - Los Angelos, CA
7 Artificial Pancreas - Closed-loop prototypes - Bihormonal therapy (glucagon/insulin) Closed-loop Prototypes: Inpatient & Outpatient Clinic Trials Artificial Pancreas Artificial Pancreas Atkinson et al: Type 1 Diabetes Lancet (2014) 383:69-82 Integrated-closed loop delivery vs conventional insulin pump therapy: closed loop delivery improved overnight control Reduced nocturnal hypoglycemia Tested in closely supervised clinical research facility setting including bihormonal closed-loop system (glucagon/insulin) Also tested ambulatory closed-loop protoype closely-monitored at patient s home in free-living conditions Garg et al: Diabetes Technol. Ther (2012) 14:205-9 Buckingham et al: Diabetes Care (2010) 33: Thabit et al: Curr Opin Endocr Diab Obes (2014) 21(2) Clinical Trials of Hybrid Closed-loop Insulin Delivery Clinical Trials of Hybrid Closed-loop Insulin Delivery Method: - 12 adolescents, two 7 day periods of sensor-augmented insulin pump therapy - Gender (M/F): 8/4 - Age: HbA1c: Duration on pump (years): Total daily insulin: Results: Sensor glucose in target range: - 72% of time Close-loop - vs 53% control period - Mean glucose: 9.4 vs 10.3 mmol/l (169 vs 185 mg/dl) Conclusions: - Unsupervised, day-andnight hybrid closed loop insulin delivery at home is feasible and safe Tauschman et al Diabetes Care 2016 Clinical trial reg. no. NCT : Clinical trial reg. no. NCT : 7
8 Hybrid Closed-loop Insulin Pump Medtronic MiniMed 670G/ Enlite 3 hybrid Closed Loop System - Clinical trial results: single-arm, multi-center home & hotel clinical investigation June 2015-May 2016 Gray: Run-In Red: Study closed loop Hybrid Closed-loop Insulin Pump Medtronic MiniMed 670G/ Enlite 3 hybrid Closed Loop System - Clinical trial results: single-arm, multi-center home & hotel clinical investigation June 2015-May % reduction in hypoglycemia (<70 mg/dl) 40% decline in glucose < 50 mg/dl 0.5% improvement in HbA1c 11% decline in time glucose > 180mg/dl ClinicalTrials.gov Identifier: NCT ClinicalTrials.gov Identifier: NCT First Artificial Pancreas approved by FDA Artificial Pancreas Prototype: Bigfoot Biomedical Pre-filled insulin cartridge Mobile app on smartphone acts as controller & user interface Dexcom G5 CGM glucose sensor Innovative Smart Insulin" Patch PNAS 112: New Technology Blinded Continuous Glucose SensorAbbott s FreeStyle Libre Pro - Approved by FDA - Applied in healthcare providers office - Worn for 2 weeks - Real-time version under FDA review 8
9 New Technology Sensor for carb content - & smart scale for serving size: Long-term Biosensor for continuous monitoring of body chemistry Pathophysiology of Insulin Resistance and Type 2 Diabetes Causes of Hyperglycemia in Type 2 Diabetes C Smoking and Diabetes: Why is there so much diabetes in Kentucky? Physicians Health Study >20 cigarettes/day RR Diabetes > 2 fold cigarettes/d RR Diabetes 1.5 fold Increased Gestational Diabetes in women who smoke Nicotine causes insulin resistance American Journal of Medicine 109(7):538, Am J Epidemiol Dec 15;160(12): How Is Smoking Related to Diabetes? smoking causes type 2 diabetes the more cigarettes you smoke, the higher your risk for type 2 diabetes smoking makes your diabetes harder to control smokers with diabetes have higher risks for serious complications Source: Intensive Therapy A1c goal: <6% The VADT Trial Study Randomization Older individuals with T2DM 1792 Primary Outcomes: Major CV events Amputation Interventions for CAD, PVD Conventional Therapy A1c goal: 8-9% Result: no difference in Major CV between Intensive and Conventional Therapy Groups 9
10 Clinical Implications: T2DM CV Trials Clinical Implications: T2DM CV Trials Control of non-glucose risk factors especially HDL reduce CV events in patients with Type 2 DM. Appropriate management of hypertension, dyslipidemia and other CV risk factors appears to be most effective at reducing cardiovascular morbidity and mortality in individuals with long-standing type 2 diabetes Intensive glucose control is beneficial if begun soon after diagnosis, but may be detrimental in long established Type 2 DM. Severe hypoglycemia is associated with an increase in CV events. Treat To Target: Clinical Inertia Objective 3: Identify current research for the prevention of diabetes Esposito et al: New guidelines for metabolic targets in diabetes Endocrine (2014) doi: /s Path to Type 1 Diabetes Genetic Risk Immune Activation Stage 1 Stage 2 Stage 3 Post- Diagnosis Normal Abnormal Clinical Blood Sugar Blood Sugar diagnosis > 2 Autoantibodies > 2 Autoantibodies > 2 Autoantibodies Battaglia et al: Understanding & Preventing T1DM through the unique working model of TrialNet. Diabetologia
11 TrialNet Sites Clinical Trials to Prevent Diabetes: Type 1 Diabetes TrialNet Study Group Conducting studies to: Test family members of people with type 1 diabetes to determine their risk to develop type 1. Learn more about common risk factors among people who develop type 1 diabetes. Test treatments that could delay or prevent onset of type 1 diabetes. Test treatments that might help people who have recently been diagnosed keep producing their own insulin. TrialNet Studies 1. Studies for people who do not have type 1 diabetes, but are at increased risk because they have a family member with the disease 2. Studies for those recently diagnosed with type 1 diabetes (within 100 days) 3. Studies for participants previously enrolled in TrialNet Studies TrialNet Studies 1. Natural History Study (TN01): Studies for people who do not have type 1 diabetes, but are at increased risk because they have a family member with the disease Over 178,648 relatives screened (as of ) Positive for one autoantibody: 3,273 Positive for 2 or > autoantibodies: 4,888 Progressed to T1DM: 835 Battaglia et al Diabetologia, 2017 TrialNet Interventions New-Onset Diabetes Anti-CD3 (via ITN collaboration) Mycophenolate Mofetil +/- Anti-CD25 Anti-CD20 Anti-CD3 +/- Exenatide Thymoglobulin (via ITN collaboration) IL-2 plus Sirolimus Phase 1 Safety Study (together with ITN) Current TrialNet Studies Pathway to Prevention Study: UK is a site please refer any first degree relative of person with type 1 diabetes to be screened - Call (859) D. Karounos, PI Anti-CD3 mab (Teplizumab) for Prevention Of Diabetes In Relatives At Risk For Type 1 Diabetes Mellitus CTLA4-Ig (Abatacept) for Prevention of Type 1 Diabetes in Relatives At-Risk 11
12 Summary Diabetes Research Group Immune therapy of diabetes will likely involve treatment with multiple agents to try to prevent destruction of islets New ultra-fast and ultra-long acting insulins will improve the therapy of diabetes Glucose sensors and insulin delivery devices now provide us with closed-loop insulin-delivery systems Dennis G. Karounos, M.D. Collaborators: - J. Scott Bryson, Ph.D. - David Randall, Ph.D. - L. Ray Reynolds, M.D. - Nicole C. Dombroski, D.O. - Derick Adams, D.O. - Matt Hager, M.D. - Robert Lodder, Ph.D. Research Coordinators: Ruth Oremus Lyndsey Dye 12
Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationDiabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018
Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationDIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson
DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson March 3 rd, 2018 Who is this guy? Accelerating Progress 1 Oh that guy! Accelerating Progress 2 STATE OF T1D CARE
More informationThe regenerative therapy of type 1 diabetes mellitus 21April 2017 Girne, Northern Cyprus 53rd Turkish National Diabetes Congress
The regenerative therapy of type 1 diabetes mellitus 21April 2017 Girne, Northern Cyprus 53rd Turkish National Diabetes Congress Thomas Linn Clinical Research Unit Centre of Internal Medicine Justus Liebig
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationDiabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018
Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018 Title of My Talk Ancient Times Diabetes has been affecting lives for thousands of years. Egyptians in
More informationThe artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes
The artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes Roman Hovorka PhD FMedSci University of Cambridge, UK Duality of interest declaration Advisory Panel: Research
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationProviding Stability to an Unstable Disease
Basal Insulin Therapy Providing Stability to an Unstable Disease Thomas A. Hughes, M.D. Professor of Medicine - Retired Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationIPS Modern management of childhood diabetes mellitus
Modern management of childhood diabetes mellitus Professor Philippe LYSY, MD PhD Pediatric endocrinology and diabetology Institut de Recherche Expérimentale et Clinique Université Catholique de Louvain
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationNovel Formulations to Modify Mealtime Insulin Kinetics
Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees
More informationGestational Diabetes: Long Term Metabolic Consequences. Outline 5/27/2014
Gestational Diabetes: Long Term Metabolic Consequences Gladys (Sandy) Ramos, MD Associate Clinical Professor Maternal Fetal Medicine Outline Population rates of obesity and T2DM Obesity and metabolic syndrome
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationWeek 3, Lecture 5a. Pathophysiology of Diabetes. Simin Liu, MD, ScD
Week 3, Lecture 5a Pathophysiology of Diabetes Simin Liu, MD, ScD General Model of Peptide Hormone Action Hormone Plasma Membrane Activated Nucleus Cellular Trafficking Enzymes Inhibited Receptor Effector
More informationJDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director
JDRF RESEARCH UPDATE Daniel Finan, Ph.D. Research Director March 10, 2018 PRESENTER Daniel Finan Biomedical engineer B.S. Chemical Engineering University of Colorado, 2003 Ph.D. Chemical Engineering UC
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationCALIPSO Project. an innovative approach to insulin therapy management
CALIPSO Project an innovative approach to insulin therapy management Preface Our project Preliminary business plan Project Team Calipso Project 2015 Why it should be so hard for diabetics to manage their
More informationCurrent Trends in Diagnosis and Management of Gestational Diabetes
Current Trends in Diagnosis and Management of Gestational Diabetes Shreela Mishra, MD Assistant Clinical Professor UCSF Fresno Medical Education Program 2/2/2019 Disclosures No disclosures 2/2/19 Objectives
More informationCase 2: A 42 year-old male with a new diagnosis of diabetes mellitus. History - 1
Case 2: A 42 year-old male with a new diagnosis of diabetes mellitus Bruce Knutsen, MD Michael Slag, MD Lisa Thomas, RN, CDE Essentia Health Diabetes and Endocrinology Conference October 14, 2011 History
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationClinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationSubject Index. Breastfeeding, self-monitoring of blood glucose 56
Subject Index Animas Vibe 86, 130 Artificial pancreas clinical studies inpatient studies 175 180 outpatient studies outcome assessment 182, 183 technology 180, 181 telemedicine 182 components glucose sensor
More informationIslet Cell Allo-Transplantation. Disclosure. Objectives
Islet Cell Allo-Transplantation Gregory P. Forlenza, MD MCR Assistant Professor Barbara Davis Center University of Colorado Denver Special thanks to Melena Bellin, MD at The University of Minnesota who
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationV. N. Karazin Kharkiv National University Department of internal medicine Golubkina E.O., ass. of prof., Shanina I. V., ass. of prof.
V. N. Karazin Kharkiv National University Department of internal medicine Golubkina E.O., ass. of prof., Shanina I. V., ass. of prof., Macharinskaya O.S., ass. of prof; Supervisor: prof. Yabluchanskiy
More informationMore Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center
More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump
Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationDiabetes Mellitus and the Dental Healthcare Professional
Diabetes Mellitus and the Dental Healthcare Professional Jerry A. Brown DMD, CDE University of South Florida Department of Internal Medicine jabrown7@health.usf.edu Learning Objectives Diabetes- The Disease
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes
Protocol Artificial Pancreas Device Systems Medical Benefit Effective Date: 07/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18, 05/18, 01/19 Preauthorization
More informationTechnology in Diabetes Management Irl B. Hirsch, MD University of Washington
Technology in Diabetes Management 2016 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia Raise Your Hand
More informationIncorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard
More informationassociated with serious complications, but reduce occurrences with preventive measures
Wk 9. Management of Clients with Diabetes Mellitus 1. Diabetes Mellitus body s inability to metabolize carbohydrates, fats, proteins hyperglycemia associated with serious complications, but reduce occurrences
More informationStaging of Type 1 Diabetes: Clinical Implications. April Deborah Hefty, MN, RN, CDE.
Staging of Type 1 Diabetes: TT Clinical Implications April 2016 Deborah Hefty, MN, RN, CDE dhefty@benaroyaresearch.org BRI s major contributions to type 1 diabetes research Identified type 1 diabetes susceptibility
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationThe Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes
The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationDiabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE
Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationPrediction and Prevention of Type 1 Diabetes. How far to go?
Prediction and Prevention of Type 1 Diabetes. How far to go? Peter Colman Diabetes and Endocrinology Royal Melbourne Hospital Royal Melbourne Hospital Lancet, Saturday 30 th November 1974; p. 1279-1282
More informationArtificial Pancreas Device System (APDS)
Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER
More informationType 1 Diabetes Update Robin Goland, MD
Naomi Berrie Diabetes Center Type 1 Diabetes Update 2008 Robin Goland, MD Type 1 diabetes is: A manageable condition A chronic condition Often challenging Entirely compatible with a happy and healthy childhood
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationCGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationInsulin 10/11/17. Disclosures. Objectives. Speaker and Consultant for Jansen and Healthscripts Speaker and Consultant for Boehringer Ingelheim (BI)
Insulin The What, When, Where, Who and Why Disclosures Speaker and Consultant for Jansen and Healthscripts Speaker and Consultant for Boehringer Ingelheim (BI) Objectives Define background and history
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationExogenous Insulin in type 2 DM
Exogenous Insulin in type 2 DM Russell Scott 2015 Part 1: Some basic biochemistry for Insulin absorption and action MY CHECK LIST Factors influencing insulin action: Forgets to inject Amount given Timing
More informationHelpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center
Helpful Hints for Taking Care of Your Diabetes Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Objectives How big of a problem is diabetes? What is diabetes? How is
More informationInsulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education
Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history
More informationInsulin Pumps and Glucose Sensors in Diabetes Management
Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationStandards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE
Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationFuture Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
Future Direction of Artificial Pancreas Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer,
More informationDIAGNOSIS OF DIABETES NOW WHAT?
DIAGNOSIS OF DIABETES NOW WHAT? DISCUSS GOALS FOR DIABETES CARE IDENTIFY COMMON COMPLIANCE- ADHERENCE ISSUES DESCRIBE TECHNOLOGY TO ASSIST AND / OR IMPROVE DIABETES CARE WHAT DO WE WANT OUR PATIENTS TO
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationDIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT
DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT Min-Jye Chen, MD Endocrinology Diabetes Management of the School-Aged Child Provided by Texas Children s Hospital Provider #18-267764-A
More informationDIABETES - FACT SHEET
DIABETES - FACT SHEET What is diabetes? Diabetes mellitus, often shortened to diabetes, is a chronic condition that affects the body's ability to control blood sugar level and use energy from food. In
More informationThe In-Clinic Close Loop Experience in the US
The In-Clinic Close Loop Experience in the US Keystone Symposium, Practical Ways to Achieve Targets in Diabetes Care July 14, 2012 Francine Ratner Kaufman, MD Chief Medical Officer, VP Global Medical,
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION
CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing
More informationAdvances Towards the Bionic Pancreas.
Advances Towards the Bionic Pancreas. Ron Brazg MD, FACE Rainier Clinical Research Center Renton, WA DISCLOSURES Rainier Clinical Research Center is an independent research facility not directly affiliated
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationPresented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Background Info A1c Average glucose levels over previous 2-3 months Currently remains gold standard for determining control Indicator of risk for development of complications
More informationDiabetes Education Columbus Community Hospital Stacy Biesel RN, CDE
Diabetes Education Columbus Community Hospital Stacy Biesel RN, CDE Stacy Biesel, RN CDE Registered Nurse Certified Diabetes Educator Locations: Columbus Community Hospital Prairie Ridge Health Clinic
More informationDiabetic Emergencies DKA, HHS, Hypoglycemia. Disclosure. Learning Objectives
Diabetic Emergencies DKA, HHS, Hypoglycemia October 2018 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Disclosure Michael McDermott has no conflict
More informationBasics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationManagement of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth
Management of Diabetes New Concepts New Devices New Medications Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Objectives: At the end of this lecture, the learner will
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationGlycemic Control IU Health Diabetes Centers
Glycemic Control IU Health Diabetes Centers Central Nursing Orientation 3/10/2014 1 Objectives Identify laboratory results that diagnosis diabetes and reflect glycemic control Describe glycemic control
More informationType 1 DM. CME Away India & Sri Lanka March 23 - April 7, 2018
Type 1 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017 by Sea
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More information